GGHC
IONS icon

Gilder Gagnon Howe & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,275
Closed -$1.52M – 264
2025
Q4 		$1.52M Buy
+19,275
New +$1.45M 0.02% 206

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Gilder Gagnon Howe & Co's IONS Position: Q1 2026 in Review

Gilder Gagnon Howe & Co sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 19,275 shares — an estimated $1.52M sold.

Gilder Gagnon Howe & Co first reported a position in IONS in Q4 2025 and held it in 1 quarter. The position peaked at $1.52M in Q4 2025. 497 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Gilder Gagnon Howe & Co reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 19,275 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.52M.
  • Gilder Gagnon Howe & Co first reported a position in Ionis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Ionis Pharmaceuticals position peaked at $1.52M in Q4 2025.
  • 497 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.